Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...